News

The ADHD Rx shortage is impacting children and their families. Here, a clinician shares how she supports her patients.

From a groundbreaking new launch for PTSD in the United States to connections between antidepressant treatment and metabolic syndrome, here are highlights from the week in Psychiatric Times.

“If approved, KarXT would represent a new mechanism of action to treat schizophrenia, which would be the first new mechanism potentially in decades.”

What is new in research on posttraumatic stress disorder?

Write to us now to be part of our series focused on clinician wellness this month.

With the upcoming election and the rising risk of COVID, here’s how we can avoid physical and psychological trauma.

New positive pivotal phase 3 study data released on oral weekly risperidone for schizophrenia.

The data assess the extended efficacy of the treatment for up to 4 years.

The device is now available at 2 US clinics, with training and installation currently underway at several other locations.

The device is currently under clinical trial investigation as an adjunct treatment to standard of care therapy for experiential negative symptoms of schizophrenia.

New study results show evenamide as an add-on to antipsychotics for treatment-resistant schizophrenia significantly reduced disease severity.

"Together we will win..."

A psychiatrist reflects on a new year and anticipatory growth.

Will this medication make me gain weight? Researchers analyzed response to antidepressant treatment as a predictor of incident metabolic syndrome in a cohort of patients with depression.

Here’s to being curious in 2024!

Here are some updates from the world of psychiatry throughout the month of December.

What is new in research on seasonal affective disorder?

Psychiatric Times chats with new Mood Disorders Section Editor Gus Alva, MD, about his new role, his interest in mood disorders, and his love of psychiatry.

The experts weighed in on a wide variety of psychiatric issues for the December 2023 issue of Psychiatric Times.

A medical student's award-winning piece on her battles with an eating disorder.

OABD is a significant concern among older adults, characterized by unique presentations and comorbidities. Here's what you need to know.

Clinicians must feel knowledgeable and masterful in incorporating lifestyle and integrative therapies targeting nutrition, stress reduction, normalization of sleep, aerobic and mindful exercise, and meaningful activities that add joy and life to years, and not just years to life.

Here are highlights from some of the year’s top features in Psychiatric Times from throughout 2023.

Review the uses and forms of transcranial magnetic stimulation.

Captagon tablets: how are they impacting the current state of world affairs?

Although psychiatric disorders are common among older adults, many of these individuals do not get the treatment they need. The Psychiatric Times Special Report on Geriatric Psychiatry discusses how we can improve outcomes for this patient population.

Reviewing a year of CMEs in Psychiatric Times®

On Christmas, a psychiatrist shares his emboldening reflections...

Here are some highlights from Frank A. Clark, MD’s, Poetry for Inclusion from throughout 2023, as seen in Psychiatric Times.

From new guidelines for the utilization of artificial intelligence in health care to the efficacy of fish oil as a replacement for antidepressants, here are highlights from the week in Psychiatric Times.